The Arabidopsis thaliana lysophospholipid acyltransferase At1g78690 acylates a variety of lysophospholipids such as lyso phosphatidylglycerol, lyso phosphatidylethanolamine and lyso phosphatidylserine. Despite di-acylate phosphatidylglycerol being a substrate, overexpression of At1g78690 in Escherichia coli leads to the accumulation of acyl-PG. Here we show that cardiolipin also accumulates in cells overexpressing At1g78690. To help try and explain this observation, we show, using a liquid chromatography mass spectrometry (LC-MS) based assay, that At1g78690 utilizes both mono-and di-lyso cardiolipin as an acyl acceptor. Because At1g78690 shares high homology (~40%) with the cardiolipin remodeling enzyme tafazzin, we also tested whether At1g78690 was able to catalyze a tafazzin-like transacylation reaction. Di-linoleoyl phosphatidylcholine was used as the acyl donor and mono-lyso cardiolipin was used as the acyl acceptor in a reaction and the reaction was monitored by LC-MS. No transfer of the linoleoyl chains was detected in an At1g78690 dependent manner suggesting that, despite the strong homology, these enzymes catalyze unique reactions.
Introduction
The Arabidopsis thaliana gene At1g78690 encodes a lysophospholipid acyltransferase that utilizes acyl-CoA to acylate mono-acylated glycerophospholipids (GPLs) to their di-acylated GPLs in vitro [1, 2] yet when it is overexpressed in Escherichia coli the headgroup acylated GPL acyl phosphatidylglycerol (acyl PG) accumulates.
At1g78690 does not, however, acylate the headgroup of PG directly [1] . Recently we have shown that At1g78690 also acylates bis(monoacylglycero)phosphate (BMP) to form acyl-PG [2] . This activity potentially explains the accumulation of acyl PG in E. coli when At1g78690 is overexpressed in vivo -endogenous BMP found in E. coli is acylated to acyl PG in vivo leading to increased levels of acyl PG.
At1g78690's closest protein homolog is the transacylase tafazzin [3] . Tafazzin has been implicated in remodeling cardiolipin, a tetra-acylated GPL [4, 5] . A mutation in the gene encoding for tafazzin, leads to an X-linked cardiomyopathy known as Barth's syndrome [6] [7] [8] . Cells deficient in tafazzin have a decreased levels of cardiolipin (CL) and elevated levels of monolysocardiolipin (MLCL), allowing MLCL/CL ratios to serve as a diagnostic tool for Barth's syndrome [4] .
As related above, tafazzin is involved in the remodeling of the cardiolipin acyl chains, converting de novo synthesized CL to primarily tetralinoleoyl CL [9] . Tafazzin catalyzes the acylation of lyso phosphatidylcholine (lyso PC) from acyl chains derived from tetra-acylated CL, and also catalyzes the reverse reaction, acylating MLCL from acyl chains derived from PC. Tafazzin displays broad acyl chain specificity under certain in vitro conditions [5, 10] , however, promotes specific remodeling of CL to tetralinoleoyl CL in the context of non-bilayer lipid membranes [11] .
At1g78690 shares 39% and 41% sequence homology to human and Drosophila melanogaster tafazzins, respectively, indicative of a shared fold and enzymatic mechanism.
Indeed, At1g78690 is likely the A. thaliana version of tafazzin and suggests that At1g78690 may possess tafazzin-like activity or play a role in modulating CL composition in vivo.
In eukaryotes, CL is found in the inner mitochondrial membrane in eukaryotes and is critical for mitochondrial function [12] . It serves as a necessary proton trap for oxidative phosphorylation and is a trigger for apoptosis. In bacteria such as E. coli, CL is also enriched at the cell poles and cell division sites [13, 14] and is involved in the osmotic stress response [15] .
Here we show that expression of At1g78690 impacts the levels of CL in E. coli in addition to the acyl-PG levels. In addition, because of the high homology of At1g78690 to tafazzin we investigated the enzyme's ability to acylate MLCL and DLCL as well as whether At1g78690 possesses taffazin-like MLCL:PC transacylase activity.
Materials and Methods

Materials
Solvents for lipid extraction were reagent grade from Sigma. High performance liquid chromatography solvents were CHROMASOLV ® Plus, HPLC grade from Sigma Aldrich. Other chemicals were purchased from VWR or Sigma-Aldrich.
Heart bovine monolysocardiolipin (MLCL), dilysocardiolipin (DLCL), 1,2-dilinoleoyl-snglycero-3-phosphocholine (18:2 PC), and 20:5-Coenzyme A were from Avanti Polar Lipids (Alabaster, AL).
Growth of E. coli and preparation of protein extracts
E. coli BLR(DE3)pLysS were transformed with pET15b and pHis-AT1g78690Lipid and grown as described previously [1] . Following harvesting by centrifugation for 20 minutes at 2600 x g, cell pellets were washed with 15 mM Tris, pH 7.4 and the centrifugation repeated to harvest cells. Cell pellets were frozen at -80 °C until further use.
Cell-free extracts and membranes were prepared as described previously [2] . Protein concentrations were determined using a bicinchoninic acid reagent (Thermo Scientific) with bovine serum albumin as the standard. All protein samples were stored at -80 °C until needed.
Preparation of in vitro enzyme products
In vitro products were generated in a 0.5 ml reaction that contained 100 µM 20:4 or 20:5-CoA, 300 µM acyl acceptor (MLCL, DLCL, or 1-acyl lyso GPL), 15 mM Tris pH 7.4, and 0.05% Triton X-100, and were initiated by the addition of 0.5 mg/mL membranes from BLR(DE3)pLysS/pET15b or BLR(DE3)pLysS/pHis-At1g78690 prepared as described previously [2] . For transacylation assays, 100 µM di-linoleoyl PC was included in place of the acyl CoA, and 300 µM MLCL as the acyl acceptor. Reactions were incubated at 37°C for 3 hours and terminated by Bligh-Dyer extraction [2, 16] . The lower phase of the two-phase system was transferred to a glass vial equipped with a glass volume reducer, dried under a stream of N2 gas and stored at -20°C until analysis.
Mass spectrometry of in vitro products
The dried products from each in vitro acylation or transacylation reaction was resuspended in 100 µL CHCl3:CH3OH (2:1 v/v) and analyzed using normal phase liquid chromatography electrospray ionization quadrupole time-of-flight mass spectrometer as described previously [2] .
Results
Overexpression of At1g78690 leads to the accumulation of CL in addition to acyl PG.
Previously we have shown that overexpression of At1g78690 leads to the accumulation of the headgroup acylated GPL acyl PG [1] . Further examination of the LC-MS profile reveals that, in addition, a number of cardiolipin species accumulate. Figure 1 shows that the total amount of cardiolipin increases in lipid extracts derived from 
MLCL and DLCL acylation
At1g78690 robustly acylates 1-acyl lyso phosphatidylethanolamine (PE), 1-acyl lyso PG, 1-acyl lyso phosphatidylserine (PS), and 1-acyl phosphatidylinositol (PI) using acyl-CoA as the acyl donor to produce PE, PG, PS, and PI, respectively [1, 2] . Since heterologous expression of At1g78690 in E. coli impacts the lipid profile by altering CL levels, and because At1g78690 has been shown to acylate various lysophospholipids, we hypothesized that At1g78690 may be acylating endogenous under-acylated CLs to form CL. Using a LC-MS based assay, we assessed whether At1g78690 can catalyze the acylation of DLCL to form MLCL, and if At1g78690 can acylate MLCL to CL. Using 20:5 acyl-CoA as the acyl donor and MLCL or DLCL as the acyl acceptor we monitored the formation of the expected products using membranes prepared from cells expressing At1g78690, and compare these products to those formed from the reaction using membranes expressing vector alone. 
MLCL:PC transacylation
Tafazzin has been shown to have phospholipid transacylase activity, capable of transferring the acyl chain from PC to acylate MLCL, forming CL and lyso PC [3] [4] [5] . Careful review of the MS data showed that no 18:2 acyl chains were detected in other phospholipid pools in an At1g78690 dependent manner. Taken together this data suggests that At1g78690 does not function as a transacylase using PC as an acyl donor.
Discussion
Lysophospholipid acyltransferases (LPLAT) within the 1-acyl-glycerol-3-phosphate O-acyltransferase (AGPAT) family [17, 18] , such as At1g78690 are necessary for generating membrane lipid diversity through the Land's cycle remodeling pathway and through de novo biosynthesis in the Kennedy pathway [19] . When the acyl-CoA dependent LPLAT At1g78690 is overexpressed in E. coli, the lipid profile is altered through increased levels of CL in addition to an increase in the headgroup acylated GPL acyl PG. Currently we hypothesize that At1g78690 is leading to increased levels of acyl PG because of its ability to acylate bis-(monoacylglycerol) phosphate (BMP) [2] and to a small extent, the headgroup of lyso PG [20] . The sequential acylation of lysoPG to BMP and then BMP to acyl PG may explain the accumulation of acyl PG despite At1g78690 not effectively acylating the sn-2 positon of PG [1] .
The increase in CL was particularly intriguing given the high homology At1g78690 shares with tafazzin [3, 4] . Despite this, At1g78690 does not appear to catalyze similar transacylation reactions. When At1g78690 was provided di-linoleoyl PC as a substrate from which to serve as any acyl donor to MLCL, the predicted product was not detected. In addition, careful review of the data showed that no other lipids contained the 18:2 acyl chains from di-linoleoyl PC in an At1g78690 dependent manner.
Recent work with tafazzin suggests that its ability to preferentially transfer 18:2 acyl chains into MLCL is dependent on lipid structural order. When the lipid substrates are present in non-bilayer lipid membranes there is a strong preference for linoleoyl acyl chains compared to oleoyl acyl chains. The impact of the lipid environment on At1g78690 remains to be investigated directly. However, the major GPL of E. coli inner membranes, where At1g78690 is presumed to be located as a peripheral membrane protein, is mainly composed of PE [21] , a non-bilayer forming lipid [22] . This suggests that the membrane environment would be suitable for At1g78690 to display tafazzin-like transacylation reactions.
The increase in CL levels observed due to At1g78690 expression may, at least in part, be the result of endogenous lyso CL acylation by At1g78690 to form CL. Cardiolipin has been noted for its role in the binding and regulation of peripheral membrane proteins in bacteria [23] . Since At1g78690 is a peripheral membrane protein, it is possible that At1g78690 expression stimulates CL biosynthesis in order for At1g78690 to be properly localized within the membrane; it remains to be investigated whether or not CL is necessary for At1g78690 function and localization in the membrane.
The increase in CL may also be in response to the lipid composition changes that occur following At1g78690 expression. The depletion of lyso-GPLs that may occur due to At1g78690 activity may lead to disruptions of the lipid bilayer inducing compensatory increases in CL. Lyso-GPLs have been shown to behave similarly to detergents with the ability to disrupt bilayers [24] . The increase in CL may somehow be fortifying the membrane in the presence of At1g78690 induced lipid composition changes.
Previously it has been shown that CL can accumulate upon overexpression of certain membrane proteins [23, [25] [26] [27] . For example, overexpression of the F-ATPase subunit b leads to the formation of intracellular cytoplasmic membranes (ICMs) that resemble mitochondrial inner cristae [25, 28] . It remains to be determined whether cells overexpressing At1g78690 also possess ICMs. 
